Drugs / WP1066
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04334863 | May 2020 → Feb 2023 | medulloblastoma, metastatic malignant neoplasm in the brain | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT01904123 | Jul 2018 → Mar 2022 | glioblastoma, metastatic malignant neoplasm in the brain, metastatic melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05879250 | May 2024 → Dec 2027 expected | IDH-wildtype glioblastoma | Northwestern University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2025-12-17 | Moleculin Biotech, Inc. | Results Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors moleculin.com ↗
Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight |
| 2022-04-21 | Moleculin Biotech, Inc. | Regulatory Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma moleculin.com ↗ |
| 2021-04-14 | Moleculin Biotech, Inc. | Regulatory Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma moleculin.com ↗ |
| 2020-12-01 | Moleculin Biotech, Inc. | Regulatory Moleculin Announces FDA Approves 3 Rare Pediatric Disease Designations for WP1066 moleculin.com ↗
today announced that the US Food and Drug Administration (FDA) has approved its request for a “Rare Pediatric Disease” designation for its drug candidate WP1066. |
| 2020-10-13 | Moleculin Biotech, Inc. | Results Moleculin Announces Additional Positive Interim Results in Adult Glioblastoma Clinical Trial moleculin.com ↗ |
| 2020-10-01 | Moleculin Biotech, Inc. | Results Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University moleculin.com ↗
One of these patients with diffuse intrinsic pontine glioma (DIPG), showed an apparent response to the treatment with both clinical improvement and radiologic reduction of tumor size. |
| 2020-07-06 | WPD Pharmaceuticals Sp. z o.o. | Results WPD Pharmaceuticals Licensor Announces Updates on Annamycin and WP1066 wpdpharmaceuticals.com ↗
Moleculin's STAT3 inhibitor, WP1066, used in combination with tr aditional whole brain radiation therapy resulted in long-term survivors and enhanced median survival time relative to monotherapy in mice with implanted human brain tumors. |
| 2020-07-01 | Moleculin Biotech, Inc. | Results New Publication Finds Combination of WP1066 and Radiation Resulted in Long-Term Survival in Human Brain Tumor Mouse Model moleculin.com ↗ |
| 2020-02-20 | WPD Pharmaceuticals Sp. z o.o. | Regulatory WPD Pharmaceuticals' Stat3 Inhibitor Received FDA Approval of Ind Status in Pediatric Brain Cancer Trial wpdpharmaceuticals.com ↗
Through Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq:MBRX), WPD’s license partner, the WP1066 drug candidate received FDA approval for Investigational New Drug ("IND") status to be used in a Phase 1 clinical trial for the treatment of children with recurrent or refractory malignant brain tumors. |
| 2020-02-10 | WPD Pharmaceuticals Sp. z o.o. | Results WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery wpdpharmaceuticals.com ↗
One of the key findings of the research is that immune -competent mice treated with both radiation and WP1066 developed an immunological memory that enabled them to prevent regrowth of the tumor after these tumor cells were reintroduced. |
| 2019-11-12 | Moleculin Biotech, Inc. | Regulatory Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial moleculin.com ↗ |
| 2019-02-05 | Moleculin Biotech, Inc. | Regulatory Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug moleculin.com ↗
today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate WP1066 for the treatment of glioblastoma, the most aggressive form of brain tumor. |
| 2018-12-06 | Moleculin Biotech, Inc. | Regulatory Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug moleculin.com ↗
today announced it has filed a request with the U.S. Food and Drug Administration (“FDA”) for Orphan Drug Status for its drug candidate WP1066. |
| 2018-12-04 | Moleculin Biotech, Inc. | Results Moleculin Announces Breakthrough Discovery for its WP1066 moleculin.com ↗
today announced that its own sponsored research has now confirmed a recent published study demonstrating the ability of its clinical-stage immuno-stimulating STAT3 inhibitor, WP1066, to inhibit a key immune checkpoint target known as PD-L1. |
| 2018-11-01 | Moleculin Biotech, Inc. | Results Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial moleculin.com ↗
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, with initial results showing bioavailability of the drug in patients. |
| 2007-01-23 | Callisto Pharmaceuticals | Results Publication of Early Research on Callisto Pharmaceutical’s Degrasyn Drug Class Suggests Potential to Treat Brain Tumors callistopharma.com ↗
Notably, WP1066 administered to mice significantly inhibited the growth of subcutaneous malignant glioma (brain cell) xenografts during the 30-day follow-up period. |
All press releases naming this drug 21 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WP1066 | “WP1066” NCT01904123 ↗ |
| Action | Inhibit | “STAT3 inhibitor WP1066” NCT01904123 ↗ |
| Modality | Small molecule | “WP1066 is an orally bioavailable, small-molecule inhibitor of activated phosphorylated STAT3 (p-STAT3)” PMID 41379553 ↗ Dec 2025 |
| Route | Oral | “Patients receive STAT3 inhibitor WP1066 orally (PO)” NCT01904123 ↗ |
| Target | STAT3 | “STAT3 inhibitor WP1066” NCT01904123 ↗ |